Abstract
We experienced a case that was considered as gefitinib-associated membranous nephropathy (MGN) in treatment for pulmonary adenocarcinoma. A female patient aged 80 who had been treated for lung cancer was referred and hospitalized at our hospital, because of nephrotic syndrome. The patient had pulmonary adenocarcinoma (cT4N2M1a) with positive for epidermal growth factor receptor (EGFR) mutation. Gefitinib, EGFR tyrosine kinase inhibitor, was initiated from 1 year and 2 months ago. At that time, proteinuria was negative. The treatment effect on lung cancer was so favorable that partial response had been maintained. However, from 4 months ago, edema of legs appeared, leading to become nephrotic syndrome. Renal biopsy was performed, and secondary MGN was diagnosed, because of deposition of peripheral IgG, mesangial IgA, and C3, as well as the deposition of peripheral IgG4, IgG1, IgG2, and weak IgG3. We considered drug-induced MGN and discontinued the administration of gefitinib. Subsequently, the proteinuria tended to decrease gradually and became negative 10 months later. However, the lung cancer recurred 3 months after discontinuation of gefitinib and another molecular target drug, erlotinib, was administered. At present, 13 months after discontinuation of gefitinib, absence of proteinuria is maintained. It has been generally considered that secondary MGN can be induced by both malignant tumor and their treatment. In the present case, the clinical course and pathological characteristics showed the secondary MGN that might be associated with gefitinib during the treatment for pulmonary adenocarcinoma. The present case, to our knowledge, may be a first case of gefitinib-associated MGN.
References
Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis. 1993;22:5–10.
Wągrowska-Danilewicz M, Danilewicz M. Glomerulonephritis associated with malignant disease of non-renal origin. A report of three cases and a review of the literature. Pol J Pathol. 1995;46:195–8.
Ross JH, McGinty F, Brewer DG. Penicillamine nephropathy. Nephron. 1980;26:184–6.
Nagahama K, Matsushita H, Hara M, et al. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39:706–12.
Sturgill BC, Shearlock KT. Membranous glomerulopathy and nephrotic syndrome after captopril therapy. JAMA. 1983;250:2343–5.
Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol. 2005;16:1188–94.
Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7.
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.
Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82:797–804.
Doi T, Mayumi M, Kanatsu K, et al. Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol. 1984;58:57–62.
Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005;68:302–10.
Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transpl. 2004;19:574–9.
Oliveira DB. Membranous nephropathy: an IgG4-mediated disease. Lancet. 1998;351:670–1.
Qu Z, Liu G, Li J, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transpl. 2012;27:1931–7.
Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7:85–95.
Jhaveri KD, Shah HH, Calderon K, et al. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013;84:34–44.
Masutani K, Fujisaki K, Maeda H, et al. Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol. 2008;12:398–402.
Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28–32.
Mori H, Hhno Y, Ito F, et al. Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib. Jpn J Clin Oncol. 2010;40:263–6.
Wan HL, Yao NS. Acute renal failure associated with gefitinib therapy. Lung. 2006;184:249–50.
Kumasaka R, Nakamura N, Shirato K, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol. 2004;22:2504–5.
Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int. 1999;56:355–77.
Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol. 2003;23:400–5.
Nakano M, Ueno M, Nishi S, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998;50:154–60.
Ito C, Fujii H, Ogura M, et al. Cetuximab-induced nephrotic syndrome in a case of metastatic rectal cancer. J Oncol Pharm Pract. 2013;19:265–8.
Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–36.
Hayman SR, Leung N, Grande JP, et al. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14:285–94.
Kijima T, Shimizu T, Nonen S, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. J Clin Oncol. 2011;29:588–90.
Conflict of interest
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kaneko, T., Shimizu, A., Aoki, M. et al. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 4, 31–37 (2015). https://doi.org/10.1007/s13730-014-0135-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-014-0135-0